KZIA Stock Summary and Trading Ideas (Kazia Therapeutics Limited - American Depositary Shares | NASDAQ:KZIA)

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Kazia Therapeutics Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol KZIA.

As of March 5, 2025, KZIA stock price climbed to $0.79 with 48,811 million shares trading.

KZIA has a beta of 2.79, meaning it tends to be more sensitive to market movements. KZIA has a correlation of 0.03 to the broad based SPY ETF.

KZIA has a market cap of $4.42 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, KZIA traded as high as $86.10 and as low as $.76.

KZIA has underperformed the market in the last year with a price return of -68.3% while the SPY ETF gained +15.2%. KZIA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -82.5% and -12.2%, respectively, while the SPY returned -3.7% and -4.6%, respectively.

KZIA support price is $.70 and resistance is $.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KZIA shares will trade within this expected range on the day.